









Markets
/
Stocks
/
nasdaq-ktta
/

Pasithea Therapeutics Corp

KTTA

0.768USD

-0.048-5.87%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

5.72MMarket Cap

LossP/E TTM



Pasithea Therapeutics Corp

0.768

-0.048-5.87%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pasithea Therapeutics Corp

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pasithea Therapeutics Corp's Score

Industry at a Glance

Industry Ranking

307 / 501

Overall Ranking

613 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pasithea Therapeutics Corp Highlights

StrengthsRisks

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Overvalued

The company’s latest PE is -0.10, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 689.05K shares, decreasing 11.24% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 9.27K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Pasithea Therapeutics Corp's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.37, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.10, which is -31.69% below the recent high of -0.07 and -5327.67% above the recent low of -5.40.

Score

Industry at a Glance

Previous score

6.37

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 307/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 3.61, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 0.80 and the support level at 0.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.00

Change

-0.39

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.014

Buy

RSI(14)

51.507

Neutral

STOCH(KDJ)(9,3,3)

65.353

Neutral

ATR(14)

0.057

High Vlolatility

CCI(14)

35.752

Neutral

Williams %R

48.000

Neutral

TRIX(12,20)

0.036

Sell

StochRSI(14)

31.475

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.792

Sell

MA10

0.756

Buy

MA20

0.755

Buy

MA50

0.763

Buy

MA100

0.741

Buy

MA200

1.050

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 9.26%, representing a quarter-over-quarter decrease of 49.32%. The largest institutional shareholder is The Vanguard, holding a total of 9.27K shares, representing 0.12% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Orca Capital GmbH

362.86K

AdvisorShares Investments, LLC

193.55K

+261.45%

Steinman (Lawrence)

66.36K

The Vanguard Group, Inc.

Star Investors

9.27K

Citadel Advisors LLC

46.86K

UBS Financial Services, Inc.

42.14K

+871.69%

Marques (Tiago Reis)

40.00K

+1.16%

Geode Capital Management, L.L.C.

16.33K

LPL Financial LLC

10.00K

Hurley Capital, LLC

3.69K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.